Stocks
Blueprint Medicines Corporation Financial Statements (BPMC) |
||||||||||
| Blueprint Medicines Corporationsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 02.08.2023 | 26.10.2023 | 15.02.2024 | 02.05.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 63.3 | 57.6 | 56.6 | 72.0 | 96.1 | 282.2 | |||
| Operating Income, bln rub | -135.4 | -128.0 | -129.0 | -105.1 | -78.8 | -440.9 | ||||
| EBITDA, bln rub | ? | -123.2 | -128.0 | -129.0 | -103.6 | -74.0 | -434.6 | |||
| Net profit, bln rub | ? | -129.6 | -132.8 | -133.7 | -110.9 | 89.1 | -288.3 | |||
| OCF, bln rub | ? | -123.0 | -130.5 | -104.5 | -78.9 | -101.5 | -415.4 | |||
| CAPEX, bln rub | ? | 2.58 | 2.55 | 6.25 | 4.67 | 1.10 | 14.6 | |||
| FCF, bln rub | ? | -125.5 | -133.0 | -110.7 | -83.6 | -102.6 | -430.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 184.3 | 183.2 | 181.0 | 175.3 | 166.9 | 706.4 | ||||
| Cost of production, bln rub | 3.18 | 2.32 | 4.55 | 1.79 | 8.00 | 16.7 | ||||
| R&D, bln rub | 112.1 | 110.1 | 110.3 | 96.0 | 83.4 | 399.7 | ||||
| Interest expenses, bln rub | 5.82 | 4.00 | 3.81 | 15.0 | 15.1 | 37.9 | ||||
| Assets, bln rub | 1 220 | 1 106 | 1 105 | 1 049 | 1 038 | 1 038 | ||||
| Net Assets, bln rub | ? | 414.3 | 311.1 | 202.6 | 130.6 | 310.7 | 310.7 | |||
| Debt, bln rub | 118.2 | 116.2 | 125.9 | 774.1 | 597.9 | 597.9 | ||||
| Cash, bln rub | 961.3 | 836.6 | 827.2 | 710.6 | 647.9 | 647.9 | ||||
| Net debt, bln rub | -843.1 | -720.4 | -701.4 | 63.5 | -50.0 | -50.0 | ||||
| Ordinary share price, rub | 45.0 | 63.2 | 50.2 | 92.2 | 94.9 | 59.5 | ||||
| Number of ordinary shares, mln | 60.1 | 60.5 | 60.7 | 60.9 | 61.6 | 61.6 | ||||
| Market cap, bln rub | 2 705 | 3 825 | 3 048 | 5 616 | 5 841 | 3 662 | ||||
| EV, bln rub | ? | 1 862 | 3 104 | 2 346 | 5 680 | 5 792 | 3 612 | |||
| Book value, bln rub | 414 | 311 | 203 | 131 | 311 | 311 | ||||
| EPS, rub | ? | -2.15 | -2.19 | -2.20 | -1.82 | 1.45 | -4.68 | |||
| FCF/share, rub | -2.09 | -2.20 | -1.82 | -1.37 | -1.67 | -6.98 | ||||
| BV/share, rub | 6.89 | 5.14 | 3.34 | 2.14 | 5.05 | 5.05 | ||||
| EBITDA margin, % | ? | -194.7% | -222.3% | -228.0% | -143.9% | -77.0% | -154.0% | |||
| Net margin, % | ? | -204.7% | -230.7% | -236.4% | -154.1% | 92.7% | -102.2% | |||
| FCF yield, % | ? | -18.6% | -13.5% | -16.1% | -8.06% | -7.36% | -11.7% | |||
| ROE, % | ? | -140.3% | -178.1% | -273.8% | -388.2% | -92.8% | -92.8% | |||
| ROA, % | ? | -47.6% | -50.1% | -50.2% | -48.3% | -27.8% | -27.8% | |||
| P/E | ? | -4.66 | -6.90 | -5.49 | -11.1 | -20.3 | -12.7 | |||
| P/FCF | -5.38 | -7.43 | -6.19 | -12.4 | -13.6 | -8.52 | ||||
| P/S | ? | 13.2 | 17.0 | 14.1 | 22.5 | 20.7 | 13.0 | |||
| P/BV | ? | 6.53 | 12.3 | 15.0 | 43.0 | 18.8 | 11.8 | |||
| EV/EBITDA | ? | -3.37 | -5.93 | -4.43 | -11.7 | -13.3 | -8.31 | |||
| Debt/EBITDA | 1.53 | 1.38 | 1.32 | -0.13 | 0.11 | 0.11 | ||||
| R&D/CAPEX, % | 4 337% | 4 309% | 1 764% | 2 054% | 7 553% | 2 741% | ||||
| CAPEX/Revenue, % | 4.08% | 4.44% | 11.1% | 6.49% | 1.15% | 5.17% | ||||
| Blueprint Medicines Corporation shareholders | ||||||||||
